Autolus Therapeutics plc American Depositary Share

Autolus Therapeutics plc has been awarded the 2026 Prix Galien UK Award for Best Biotechnology Product by the Galien Foundation, recognizing excellence in its next-generation T cell therapy development. The award was presented by a committee of 12 UK healthcare experts and reflects the company's commitment to translating scientific research into ...

Autolus Therapeutics plc announced it will present at William Blair's 46th Annual Growth Stock Conference on June 2, 2026, and the Jefferies Global Healthcare Conference on June 3, 2026, with CEO Dr. Christian Itin as presenter. The company also announced the online publication of an abstract for the American Society of Clinical Oncology Annual M...

Autolus Therapeutics reported $74.3 million in full-year 2025 AUCATZYL net product revenue and $23.3 million in Q4 2025 revenue. The company launched AUCATZYL in the UK following NICE approval and expects 2026 revenue of $120-135 million with a shift to positive gross margin. Real-world data from the ROCCA consortium confirmed high clinical activ...

Autolus Therapeutics plc announced participation in two upcoming investor conferences in March 2026 (TD Cowen Health Care Conference on March 3 and Jefferies Biotech on the Beach Summit on March 10). The company also announced preliminary unaudited fourth quarter and full year 2025 net product revenue from AUCATZYL® sales, along with pipeline ad...

The National Institute for Health and Care Excellence (NICE) has recommended AUCATZYL®, a CAR T cell therapy developed by Autolus Therapeutics, as a treatment option for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia in England and Wales.